IHC analysis of prostatic adenocarcinoma indicated that CSF-1R expression was higher in metastatic tissue compared to non-metastatic controls, and the receptor was expressed by both cancer and stromal cells [21]. The gene discussed is CSF1R; the disease is cancer.